Literature DB >> 8153630

Differential complementation of Bcr-Abl point mutants with c-Myc.

D E Afar1, A Goga, J McLaughlin, O N Witte, C L Sawyers.   

Abstract

A complementation strategy was developed to define the signaling pathways activated by the Bcr-Abl tyrosine kinase. Transformation inactive point mutants of Bcr-Abl were tested for complementation with c-Myc. Single point mutations in the Src-homology 2 (SH2) domain, the major tyrosine autophosphorylation site of the kinase domain, and the Grb-2 binding site in the Bcr region impaired the transformation of fibroblasts by Bcr-Abl. Hyperexpression of c-Myc efficiently restored transformation activity only to the Bcr-Abl SH2 mutant. These data support a model in which Bcr-Abl activates at least two independent pathways for transformation. This strategy may be useful for discerning signaling pathways activated by other oncogenes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8153630     DOI: 10.1126/science.8153630

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  42 in total

1.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

Review 2.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 3.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

4.  The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.

Authors:  X Zhang; R Subrahmanyam; R Wong; A W Gross; R Ren
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

5.  The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

Authors:  M S Neshat; A B Raitano; H G Wang; J C Reed; C L Sawyers
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

6.  c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis.

Authors:  Olivia Furstoss; Karel Dorey; Valérie Simon; Daniela Barilà; Giulio Superti-Furga; Serge Roche
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

7.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.

Authors:  M L Gishizky; D Cortez; A M Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases.

Authors:  L Cohen; R Mohr; Y Y Chen; M Huang; R Kato; D Dorin; F Tamanoi; A Goga; D Afar; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1.

Authors:  Jidong Zhu; John Blenis; Junying Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.